Surbiton, UK -- Biomaterials and medical device developer AorTech International plc has appointed Dr Ian Griffiths as chief operating officer. Before joining Sutton, UK-headquartered AorTech, Griffiths had 15 years of experience in biomaterials in leading companies, most recently as the founding ceo of PolyNovo, am Australian developer of biodegradable polymers.
"I am delighted to have Dr Griffiths on board during this period of growth for AorTech. His expertise will be a key asset as we expand our product portfolio and regional presence," said Frank Maguire, AorTech chief executive officer, in the company's 25 March announcement. Maguire said Griffiths will be primarily responsible for Aortech's global commercial strategy and for sales outside the US, as well as for managing business development.
AorTech develops and makes medical materials, including Elast-Eon, a long-term implantable copolymer of silicone and polyurethane. According to the company, this bio-compatible material has been used for more than one million long-term human implants, and is currently used in cardiology, orthopedic, urologic and gastroenterologic areas, in devices such as pacing leads, cardiac cannulae and stents.
Devices made using Elast-Eon have multiple US FDA PMA approvals, CE Marks, Japanese Ministry of Health and Australian TGA approval. AorTech operates a 22000 sq.ft (2000 sq.m) manufacturing and distribution centre, certified to ISO 9001 and ISO 1345, in Melbourne, Australia.
Aortech says Elast-Eon's biostability is comparable to that of silicone, and it exhibits excellent mechanical, blood contacting and flex-fatigue properties. It can be processed using conventional thermoplastic extrusion and moulding techniques.